Oncolytics Biotech Inc. promoted Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer. Dr. Heineman has over two decades of experience successfully leading clinical development programs and previously served as Oncolytics' Global Head of Clinical Development and Operations. Prior to joining Oncolytics, Dr. Heineman was Senior Vice President and Head of Clinical Development at Denovo Biopharma and Vice President and Head of Clinical Development at both Genocea Biosciences and Halozyme Therapeutics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 CAD | 0.00% | -1.37% | -19.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.55% | 79.41M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Oncolytics Biotech Inc. Promotes Thomas C. Heineman to Chief Medical Officer